Immunological aspects of cancer chemotherapy
Laurence Zitvogel, Lionel Apétoh, François Ghiringhelli et al. · Nature reviews. Immunology · 2007
Cited by 1,707 works. doi:10.1038/nri2216
Authors
References
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
- Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
- Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
- Calreticulin exposure dictates the immunogenicity of cancer cell death
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses